A National, Multicenter, Non-Comparative Study Evaluating the Efficacy of the Combination of Levofloxacin (500 mg) and Rifampicin (600 or 900 mg Depending on Weight) Administered Once Daily by Oral Route, as Replacement of Empirical Antibiotic Therapy Given Intravenously With a Total Duration of 6 Weeks of the Antibiotic Therapy, in the Treatment of OsteoArticular Prosthetic Infections (OAPI), With a Two-Stage Revision of the Prosthesis.

Trial Profile

A National, Multicenter, Non-Comparative Study Evaluating the Efficacy of the Combination of Levofloxacin (500 mg) and Rifampicin (600 or 900 mg Depending on Weight) Administered Once Daily by Oral Route, as Replacement of Empirical Antibiotic Therapy Given Intravenously With a Total Duration of 6 Weeks of the Antibiotic Therapy, in the Treatment of OsteoArticular Prosthetic Infections (OAPI), With a Two-Stage Revision of the Prosthesis.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2011

At a glance

  • Drugs Levofloxacin; Rifampicin
  • Indications Bacterial infections; Bone and joint infections
  • Focus Therapeutic Use
  • Acronyms LEVOS
  • Sponsors Sanofi
  • Most Recent Events

    • 26 May 2010 Actual patient number (10) added as reported by ClinicalTrials.gov.
    • 26 May 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 11 Mar 2010 Planned end date changed from 1 Jun 2013 to 1 Apr 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top